Opinion & Commentary
Halt of Merck's HIV Vaccine Trial Should Not "Slow Progress" Toward Future Vaccine Development, Opinion Piece Says
September 27, 2007
Although many people "felt robbed" by the announcement last week that Merck's trial of an experimental HIV vaccine had been halted, it would be "worse [to] allow the news to slow progress" toward development of future HIV vaccines, Seth Berkley, president and CEO of the International AIDS Vaccine Initiative, writes in a Los Angeles Times opinion piece (Berkley, Los Angeles Times, 9/27).
HIV/AIDS vaccine research "needs fresh, bold approaches, including ideas from other fields," Berkley writes, adding that "[s]ecuring funding for this vital but long-term work is a challenge." When Congress considers "spending priorities" in reauthorizing the President's Emergency Plan for AIDS Relief, it "should guarantee that AIDS vaccine work is also well-funded," Berkley writes, concluding, "If the U.S. doesn't refill the chest with hope, who will?" (Berkley, Los Angeles Times, 9/27).
Dallas County, Texas, Must Cover $280,000 in Unpaid HIV/AIDS-Related Hospital Bills for Nonresidents, Officials Say
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.